Provided by Tiger Trade Technology Pte. Ltd.

Veru Inc.

2.47
-0.0800-3.14%
Pre-market: 2.470.00000.00%05:10 EDT
Volume:1.52M
Turnover:3.94M
Market Cap:42.11M
PE:-4.22
High:2.75
Open:2.54
Low:2.44
Close:2.55
52wk High:7.33
52wk Low:2.05
Shares:17.05M
Float Shares:15.48M
Volume Ratio:15.80
T/O Rate:9.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5854
EPS(LYR):-1.5517
ROE:-64.54%
ROA:-54.03%
PB:1.48
PE(LYR):-1.59

Loading ...

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
4 hours ago

Veru Initiated at Buy by WestPark Capital

Dow Jones
·
16 hours ago

Veru initiated with a Buy at WestPark Capital

TIPRANKS
·
17 hours ago

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Yesterday

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

Veru Plans Phase 2 Trial of Oral Sabizabulin in Daraxonrasib-Resistant Metastatic Pancreatic Cancer

Reuters
·
Sep 08

Veru - to Advance Oral Sabizabulin for Metastatic Pancreatic Cancer Resistant to Daraxonrasib

THOMSON REUTERS
·
Sep 08

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ Rasonque™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

THOMSON REUTERS
·
Sep 08

Veru CEO Steiner to Join Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 02

Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares

Reuters
·
Aug 18

Veru Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Switzerland's MoonLake Q2 Net Loss Narrows as Expenses Fall

Reuters
·
Aug 10

Veru Q3 Net Loss Narrows on Lower G&A Expenses

Reuters
·
Aug 10